Legend Biotech Corporation
LEGN
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.0B
$21.76
▼ -0.59%
P/E
-72.53
Mkt Cap
$4.0B
52-Wk Range
$16.24–$37.50
52-Week Range
$16.24 - $37.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 39.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Strong growth ahead
Value
Valuation data unavailable
Momentum
Falling
-39.2% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LEGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of $0.09 vs $0.07 consensus (+28.6% surprise). Revenue of $387.5M vs $356.0M expected (+8.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+28.6%
Revenue trend · last 1Q
—
Q1 26
$305.1M
Margins · last 1Q
Profit
-17.8%
Wall Street consensus
7 analysts · 57% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
57%
Hold
43%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Aug 12, 2026
vs Industry
How LEGN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.